Table 1 Reported COVID-19 vaccine efficacy data from phase III trials

From: Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Vaccine manufacturer (vaccine name)a Platform Clinical trial regime Total trial size Efficacy End point measure Eligibility Duration of follow up for phase III trial Circulating genotypes at location and time of trial Results by severity
Pfizer–BioNTech (BNT162b2)2 mRNA 2 doses (21 days apart) 43,548 95% Symptomatic COVID-19 and positive RT–PCR test result >16 years old Up to 24 months after second dose (NCT04368728) B.1.351, P.1, B.1.427/B.1.419, P.2 and B.1.526 100% effective in preventing CDC-defined severe disease; 95.3% effective in preventing FDA-defined severe disease
Moderna (mRNA-1273)3 mRNA 2 doses (28 days apart) 30,420 94% Symptomatic COVID-19 and positive RT–PCR test result ≥18 years old (12 years old to younger than 18 years (NCT04649151) and 6 months old to younger than 12 years (NCT04796896)) Up to 24 months after second dose (NCT04470427) B.1.427/B.1.429 and B.1.526 100% efficacy against severe disease
AstraZeneca–University of Oxford (AZD1222 (Vaxzevria, also called Covishield when manufactured by SII under license))4 Viral vector 2 doses (<6 weeks apart) 17,178 55% Symptomatic COVID-19 and positive NAAT result ≥18 years old (WHO); ≥40 years old and not pregnant in UK 24 months after first dose (NCT04516746) B.1.1.7, B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526 and C.37 100% efficacy against hospitalization
2 doses (>12 weeks apart) 81%
(Pooled efficacy 67%)
12 months after second dose (NCT04400838, NCT04536051 and NCT04516746)
Johnson & Johnsonb (Ad26.COV2-S)5,51 Viral vector 1 dose 44,325 66% Symptomatic COVID-19 and positive RT–PCR test result ≥18 years old 25 months (NCT04505722) and 27 months (NCT04614948) after first dose B.1.351, P.1, B.1.427/B.1.429, P.2, B.1.526 and C.37 85.4% efficacy against severe–critical disease occurring ≥28 days after vaccination
Gamaleyab (Sputnik V)6 Viral vector 2 doses (21 days apart) 19,866 92% Symptomatic COVID-19 and positive RT–PCR test result ≥18 years old 6 months after first dose (NCT04656613 and NCT04642339) No variants have been identified originating from the trial locations from the trial start date to the present (June 2021) No data available (June 2021)
Bharat Biotechb (Covaxin)9 Viral vector 2 doses (28 days apart) 25,800 78% Symptomatic COVID-19 and positive RT–PCR test result at least 14 days after second dose ≥18 years old (2–18 years old: study ongoing) 12 months after second dose (NCT04641481); paediatric cohort followed up for 9 months (NCT04918797) Phase III trial began on 16 November 2020 and is ongoing in India; variants identified include B.1.617.2 and B.1.617.1 100% efficacy against hospitalization
Sinovac Biotech (CoronaVac)7 Inactivated virus 2 doses (14 days apart; 14 or 28 days apart in Chile) 2,300 (Chile); 13,000 (Turkey); 12,688 (Brazil) Multiple studies in different countries: 50.7% (Brazil), 56.5% (Chile), 65% (Indonesia), 78% (Brazil) and 91% (Turkey) Symptomatic, virologically confirmed COVID-19 occurring from 2 weeks after the second dose up to 1 year after the first dose ≥18 years old 12 months after first dose P.1 and P.2 51% efficacy against symptomatic SARS-CoV-2 infection; 100% efficacy against severe disease; 100% efficacy against hospitalization from 14 days after second dose
Sinopharm (BBIBP-CorV)7 Inactivated virus 2 doses (21 days apart) 45,000 78% Occurrence of COVID-19 ≥18 years old 12 months after first dose (NCT04510207) No variants have been identified originating from the trial locations during this time (June 2021) 79% efficacy against hospitalization
Novavaxb (NVX-CoV2373)8,46,65 Protein subunit 2 doses (21 days apart) >15,000 89% Symptomatic COVID-19 and positive RT–PCR test result at least 7 days after second dose ≥18 years old (12–17 years old: study ongoing, NCT04611802) 24 months after first dose (NCT04611802) B.1.1.7, B.1.351, B.1.427/B.1.429 and B.1.526 100% efficacy against severe disease and hospitalization
VECTOR (EpiVacCorona) (NCT04780035) Protein subunit 2 doses (21–28 days apart) 3,000 No data available (June 2021) Symptomatic COVID-19, laboratory confirmed COVID-19 within 6 months after first dose ≥18 years old 9 months after first dose (NCT04780035) No variants have been identified originating in the trial locations during this time (June 2021) No data available (June 2021)
  1. CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration; NAAT, nucleic acid amplification test; RT–PCR, reverse transcription–polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SII, Serum Institute of India; WHO, World Health Organization. aVaccines in bold have been approved for use. bData extracted from interim analysis.